Buyback wouldn't make any sense. For a company at this stage of maturity, it is revenue growth and gross margin that counts. To get the growth, they will need to make investments. FDA progress has been a lot slower than hoped for, and that's the thing they need to focus on, and once FDA is approved, kick off effective sales. In Britain, they snatched a sale in Wales. If they could do this for the whole of Britain, and then Europe, that would already been very significant.
Buyback wouldn't make any sense. For a company at this stage of...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
67.5¢ |
Change
0.005(0.75%) |
Mkt cap ! $153.1M | |||
| Open | High | Low | Value | Volume |
| 67.5¢ | 67.5¢ | 67.5¢ | $36.16K | 53.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45052 | 67.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 68.0¢ | 189522 | 2 |
View Market Depth
| Last trade - 11.49am 27/09/2024 (20 minute delay) ? |
| GSS (ASX) Chart |